CalciMedica is trading at $2.22, up +5.64% after Nasdaq closed its market-value compliance matter on September 2, 2026.

  • The company satisfied Nasdaq’s alternative stockholders’ equity requirement, reporting $5.513 million as of June 30, 2026, above the applicable threshold.
  • Delisting concerns eased, although the separate $1.00 minimum-bid-price requirement remains unresolved, supporting continued volatility.